Quick Answer
Corvus Pharmaceuticals, Inc. reported Stockholders Equity of $61.21 million for the year ending 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +87.9% in Stockholders Equity from 2024 to 2025.
- This data is from Corvus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $152.55 million | Q2 2016: $151.97 million | Q3 2016: $142.91 million | Q1 2017: $118.23 million | Q2 2017: $104.78 million | Q3 2017: $93.74 million | Q1 2018: $137.23 million | Q2 2018: $127.40 million | Q3 2018: $118.85 million | Q1 2019: $100.70 million | Q2 2019: $89.65 million | Q3 2019: $80.41 million | Q1 2020: $60.04 million | Q2 2020: $50.84 million | Q3 2020: $42.35 million | Q1 2021: $94.39 million | Q2 2021: $96.40 million | Q3 2021: $105.15 million | Q1 2022: $89.72 million | Q2 2022: $80.39 million | Q3 2022: $64.68 million | Q1 2023: $48.87 million | Q2 2023: $49.48 million | Q3 2023: $44.29 million | Q1 2024: $33.36 million | Q2 2024: $51.23 million | Q3 2024: $12.41 million | Q1 2025: $49.33 million | Q2 2025: $80.23 million | Q3 2025: $71.77 million.
- Over the full 12 years of available data (2014 to 2025), Corvus Pharmaceuticals, Inc.'s Stockholders Equity has grown by 38,593.7%.
- Historical annual values: Fiscal year 2025: $61.21 million | Fiscal year 2024: $32.57 million | Fiscal year 2023: $38.68 million | Fiscal year 2022: $56.12 million | Fiscal year 2021: $97.16 million | Fiscal year 2020: $72.15 million | Fiscal year 2019: $71.11 million | Fiscal year 2018: $110.34 million | Fiscal year 2017: $84.84 million | Fiscal year 2016: $132.80 million | Fiscal year 2015: -$31.10 million | Fiscal year 2014: -$159.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: